Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Odronextamab Shows Efficacy, Safety in R/R DLBCL After Progression Post–CAR T-Cell Therapy

February 21st 2025

Odronextamab produced durable responses in relapsed/refractory diffuse large B-cell lymphoma after disease progression following CAR T-cell therapy.

Epcoritamab Elicits Durable CR Rates, Increases MRD Negativity in Relapsed/Refractory DLBCL

February 20th 2025

Julie M. Vose, MD, MBA, discusses the 3-year follow-up data with epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Epcoritamab Gains Japanese Approval for R/R Follicular Lymphoma

February 20th 2025

The Ministry of Health, Labour, and Welfare in Japan has approved epcoritamab for relapsed or refractory follicular lymphoma.

Dr Lee on the Real-World Safety Profile of Axi-Cel in R/R LBCL

February 18th 2025

Dasom (Caroline) Lee, MD, details the safety results of second-line axicabtagene ciloleucel in real-world patients with relapsed/refractory LBCL.

Five Under 5: Top Oncology Videos for the Week of 2/9

February 16th 2025

The top 5 videos of the week cover insights in plexiform neurofibromas, melanoma, myeloma, leukemia, and LBCL.

The OncFive: Top Oncology Articles for the Week of 2/9

February 15th 2025

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

Zamto-Cel Delivers Responses in R/R Diffuse Large B-Cell Lymphoma

February 14th 2025

Zamto-cel produced responses and was associated with low rates of CD19 and/or CD20 antigen loss in relapsed/refractory diffuse large B-cell lymphoma.

FDA Approves Brentuximab Vedotin Plus Lenalidomide/Rituximab for R/R LBCL

February 12th 2025

The FDA approved brentuximab vedotin plus lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma.

Liso-Cel Generates Responses in R/R Marginal Zone Lymphoma

February 10th 2025

Lisocabtagene maraleucel elicited a statistically significant overall response rate in adult patients with relapsed/refractory MZL.

Five Under 5: Top Oncology Videos for the Week of 2/2

February 9th 2025

The top 5 videos of the week cover insights in lung cancer, multiple myeloma, breast cancer, and follicular lymphoma.

Pola-R-CHP Generates Long-Term PFS and DFS Advantages vs R-CHOP in Untreated DLBCL

February 7th 2025

Polatuzumab vedotin plus R-CHP improved PFS and DFS vs R-CHOP at 5 years in previously untreated patients with diffuse large B-cell lymphoma.

Dr Alderuccio on Loncastuximab Tesirine With Rituximab in R/R Follicular Lymphoma

February 6th 2025

Juan Pablo Alderuccio, MD, discusses the combination of loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma.

Axi-Cel Shows Durable Responses, May Have Curative Potential in R/R Indolent Non-Hodgkin Lymphoma

February 4th 2025

Sattava S. Neelapu, MD, discusses updated data from the 5-year follow-up analysis evaluating axi-cel in relapsed/refractory indolent non-Hodgkin lymphoma.

Dr Amengual on the Efficacy of Tazemetostat Plus Lenalidomide/Rituximab in Follicular Lymphoma

February 4th 2025

Jennifer Amengual, MD, discusses the efficacy of tazemetostat plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

Other Key Follicular Lymphoma Data From ASH 2024

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024.

Data for Mosunetuzumab in Newly Diagnosed Follicular Lymphoma

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.

2-Year Follow-Up Data for Liso-Cel in R/R Follicular Lymphoma

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.

CD19 Expression Loss and Tafasitamab in R/R DLBCL

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss CD19 expression and the use of tafasitamab in relapsed/refractory DLBCL.

Clinical Experience Using Tafasitamab Plus Lenalidomide in DLBCL

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss their clinical practice experience using tafasitamab in relapsed/refractory DLBCL.

The Phase 3 inMIND Trial: Tafasitamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for tafasitamab in relapsed/refractory follicular lymphoma.